<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007601.ref060">
 <label>60</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Alfaro</surname>
   <given-names>C</given-names>
  </name>, 
  <name>
   <surname>Suarez</surname>
   <given-names>N</given-names>
  </name>, 
  <name>
   <surname>Gonzalez</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Solano</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Erro</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>Dubrot</surname>
   <given-names>J</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes</article-title>. 
  <source>Br J Cancer</source>. 
  <year>2009</year>;
  <volume>100</volume>(
  <issue>7</issue>):
  <fpage>1111</fpage>â€“
  <lpage>9</lpage>. Epub 2009/03/12. 
  <pub-id pub-id-type="doi">10.1038/sj.bjc.6604965</pub-id> ; PubMed Central PMCID: PMCPmc2670006.
  <?supplied-pmid 19277038?>
  <pub-id pub-id-type="pmid">19277038</pub-id>
 </mixed-citation>
</ref>
